Vonderheid-Guth B, Todorova A, Wedekind W, Dimpfel W
Pro Science Private Research Clinic GmbH, Kurt-Schumacher-Str. 9, D-35440 Linden, Germany.
Eur J Med Res. 2000 Nov 30;5(11):473-83.
The aim of this analysis was to verify objective correlates of the clinical improvement of migraine in patients by means of quantitative topographical EEG (qEEG).
Overall 40 migraine-outpatients participated in this retrospective analysis of prophylactic migraine treatment over 3-8 months with 1600 to 2000 mg cyclandelate daily. In all patients qEEG was recorded and analysed using the Fast Fourier Transformation and the determination of the Abberation Index (AI = the statistical probability of belonging to a qEEG reference group of healthy people, n = 500).
A clinical response (> 50% reduction of migraine attack frequency and duration) was observed in 77.5% (n = 31). The number and duration of migraine attacks per month (median values) were reduced in a highly significant manner. In this observation 75% of all patients investigated showed a pathological positive Aberration Index at a single electrode or a cluster of neighbouring brain sites. This consisted in a power increase in theta, alpha and/or beta1 activity, and 73.3% of them had also a corresponding negative AI-focus (power decrease). In 15 patients EEG aberrations (positive AI clusters) within one frequency band were found, whereas 15 patients showed aberrations in more than one frequency. Positive AI s were mainly found in fronto-temporal and occipital brain areas with one single topographical difference between the patients with and without aura.
Positive AI values were the main electrophysiological findings in these migraine patients. This was supported by the highly significant decrease of the median amount of the positive AI after clinically successful treatment with cyclandelate. Twenty four out of thirty patients with positive AI foci showed concurrence between qEEG-changes and clinical response. Patients with positive AI foci involving the lower or middle frequencies (theta and/or alpha 1) seemed to show a better clinical response (84.6%) than those with AI foci with participation of only faster frequencies (alpha 2 and/or beta 1; 54.5%). A controlled study is needed to confirm these observations.
本分析旨在通过定量地形图脑电图(qEEG)验证偏头痛患者临床改善的客观相关因素。
共有40名偏头痛门诊患者参与了这项为期3 - 8个月的预防性偏头痛治疗回顾性分析,患者每日服用1600至2000毫克环扁桃酯。对所有患者进行qEEG记录,并使用快速傅里叶变换和异常指数测定(AI = 属于500名健康人的qEEG参考组的统计概率)进行分析。
77.5%(n = 31)的患者出现临床反应(偏头痛发作频率和持续时间降低> 50%)。每月偏头痛发作的次数和持续时间(中位数)显著减少。在该观察中,75%的受调查患者在单个电极或相邻脑区簇处显示病理性阳性异常指数。这表现为θ、α和/或β1活动的功率增加,其中73.3%的患者也有相应的阴性AI焦点(功率降低)。15名患者在一个频带内发现脑电图异常(阳性AI簇),而15名患者在多个频率出现异常。阳性AI主要出现在额颞叶和枕叶脑区,有先兆和无先兆患者之间存在单一地形差异。
阳性AI值是这些偏头痛患者的主要电生理发现。环扁桃酯临床治疗成功后,阳性AI中位数显著下降支持了这一点。30名有阳性AI焦点的患者中有24名显示qEEG变化与临床反应一致。涉及低频或中频(θ和/或α1)的阳性AI焦点患者似乎比仅涉及较快频率(α2和/或β1)的AI焦点患者有更好的临床反应(84.6%对54.5%)。需要进行对照研究来证实这些观察结果。